GlassScriptPhysician profile
Eduardo Valenzuela
NPI 1649407677
$3,697.62
in general payments reported to CMS, 2019-2025
21 companies · $707 in 2025
The $707 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $420 · 2021: $404 · 2022: $588 · 2023: $701 · 2024: $497 · 2025: $707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,905.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $857.90 | 2021-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $447.03 | 2019-2024 | |
| Sobi, INC | $391.70 | 2019-2023 | |
| Tris Pharma INC | $357.23 | 2019-2023 | Quillivant, Quillichew Er, Dyanavel Xr |
| Cranial Technologies, INC | $300.71 | 2019-2025 | Doc Band |
| Pfizer INC. | $222.94 | 2019-2024 | |
| Organon LLC | $168.79 | 2025 | Vtama |
| Acadia Pharmaceuticals INC | $166.30 | 2024-2025 | Daybue |
| Glaxosmithkline, LLC. | $145.63 | 2019-2023 | Bexsero |
| Merck Sharp & Dohme LLC | $124.00 | 2019-2024 | Vaxelis, Gardasil, M-M-R II |
| Kyowa Kirin, INC. | $102.92 | 2025 | |
| Jazz Pharmaceuticals INC. | $100.04 | 2025 | |
| Collegium Pharmaceutical, INC. | $84.25 | 2025 | Jornay Pm |
| Ucb, INC. | $60.34 | 2024 | Nayzilam |
| Takeda Pharmaceuticals U.S.A., INC. | $32.96 | 2020-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $30.98 | 2021-2023 | Qelbree |
| Shire North American Group INC | $30.71 | 2019 | |
| Nestle Healthcare Nutrition INC. | $23.17 | 2023 | |
| Sanofi-Aventis U.S. LLC | $18.99 | 2023 | |
| Kaleo, INC. | $17.28 | 2024 | Auvi-Q |
| Azurity Pharmaceuticals, INC. | $13.75 | 2025 | Alvesco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eduardo Valenzuela listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.